Loading...
•
Mar 31, 2022
Ionis Q1 2022 Earnings Report
Ionis reported a strong start to the year with progress in its pipeline and revenues that grew more than 25 percent year over year.
Key Takeaways
Ionis Pharmaceuticals reported first quarter financial results with total revenues of $142 million, a GAAP net loss of $65 million, and $2.1 billion in cash and short-term investments. The company is on track to achieve its 2022 financial guidance.
Total revenues were $142 million.
GAAP operating expenses were $199 million.
GAAP net loss was $65 million.
Cash and short-term investments totaled $2.1 billion.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.comCollaborative agreements Revenue
CapyFin.com Forward Guidance
Ionis is on track to achieve its 2022 financial guidance. With $2.1 billion of cash, the company is well capitalized to continue investing in its large agenda to drive substantial future growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income